Ivan Kairatov joins us today to share his deep expertise in biopharmaceutical innovation, particularly within the specialized field of rare kidney diseases. With a career rooted in the research and development of transformative therapies, Kairatov offers a unique perspective on the shifting landscape of nephrology and the critical role of complement inhibitors. Our conversation today centers on the recent regulatory milestones for Ultomiris, a treatment that has recently gained FDA Priority Review for immunoglobulin A nephropathy (IgAN). We explore the physiological mechanics of renal damage, the compelling clinical outcomes from the Phase 3 I CAN trial, and the broader implications for the hundreds of thousands of patients currently facing the prospect of end-stage kidney disease.
The recent clinical data from the I CAN phase 3 trial has sparked significant interest in the medical community; could you walk us through the significance of the 46.6% reduction in proteinuria and what this means for patients in the long term?
Seeing a 46.6% reduction in the 24-hour urine protein creatinine ratio is a monumental achievement in a field where patients often feel like they are in a losing race against time. This reduction was not just statistically significant but remarkably rapid, appearing as early as week 10 and holding steady through the 34-week mark, which provides a profound sense of relief for both clinicians and their patients. When you compare that sharp decline to the mere 5.6% reduction observed in the placebo group, the resulting 43.4% placebo-adjusted treatment effect becomes a powerful indicator of the drug’s potential. For the more than 217,000 people in the United States currently diagnosed with this condition, these numbers represent a tangible, data-driven hope that we can finally slow the march toward the exhausting reality of dialysis. It is a heavy burden to live with the knowledge that your kidneys are failing, and seeing such a swift response in protein levels offers a sense of control over a previously relentless disease.
IgAN is known for its complex inflammatory process that targets the kidneys; how does the role of a C5 complement inhibitor specifically address the damage caused to the glomeruli?
To understand the value of a C5 inhibitor like Ultomiris, one must look at the destructive path of abnormal IgA proteins that settle into the kidneys and trigger the terminal complement system. This activation leads to complement-driven inflammation, which acts like a slow, hot fire burning through the glomeruli, the delicate filters responsible for cleaning and cleaning our blood. By introducing a C5 inhibitor, we are essentially aiming to quench that inflammatory fire before it leads to the irreversible scarring and loss of essential kidney cells. The beauty of this specific approach, as seen in the trial results presented at the 2026 European Renal Association Congress, is its consistency across diverse patient groups with varying disease severities. We are moving away from broad, blunt treatments and toward a precise intervention that protects the very architecture of the kidney from being dismantled by the body’s own immune response.
With the FDA granting Priority Review for this supplemental Biologics License Application, how do you perceive the impact of this accelerated timeline on the current standard of care?
The decision to grant Priority Review underscores the urgent need for new disease-modifying approaches, as many patients currently progress to end-stage kidney disease despite the treatments available today. Anticipating an FDA action date in the fourth quarter of 2026 creates a clear roadmap for a new era in nephrology where we don’t just manage the symptoms of kidney stress, but intervene directly in the underlying disease process. The safety profile observed in the I CAN trial remained consistent with what we already know about ravulizumab, which adds a vital layer of confidence for providers who are often wary of new safety concerns in fragile patient populations. Furthermore, the medical community is eagerly awaiting the week 106 data regarding the estimated glomerular filtration rate, as this will provide the definitive proof of long-term kidney preservation. It is a transition from a reactive “wait and see” mindset to a proactive, protective strategy that could redefine the life expectancy of those diagnosed.
What is your forecast for the treatment of IgAN?
I believe we are entering a phase where the standard of care will be completely redefined from simple blood pressure management to sophisticated, targeted biological interventions that stop damage before it starts. With over 217,000 Americans currently diagnosed and many more worldwide, the successful integration of C5 inhibitors will likely pave the way for earlier diagnoses and much more aggressive treatment strategies to prevent renal failure. We are moving toward a future where end-stage kidney disease is no longer an inevitable destination for IgAN patients, but rather a hurdle that can be successfully bypassed through early and precise medical action. In the coming years, the focus will likely shift toward combining these targeted therapies to ensure that the glomeruli remain functional for a lifetime, effectively turning a progressive disease into a manageable, chronic condition.
